The drug can now be used to treat locally advanced head and neck cancer prior to chemoradiotherapy and surgery, Sanofi-Aventis said in a statement.
Advanced clinical trials showed that using Taxotere in combination with standard induction chemotherapy resulted in a more than three year improvement in patient survival rate, the company said.
More than 640,000 people worldwide are diagnosed with head and neck cancer each year, and more than 350,000 die from the disease annually, the company said.
Sanofi-Aventis' shares were down 0.1 percent at EUR59.33 (US$84.12) in Paris.
"We should use shock therapy to sober up the Americans. In this case, the Americans will speak about the need to resume dialogue. There is no other option"
The United States is concerned about the current crisis in the relations with Russia and suggests returning to reasonable policies to avoid a nuclear war